NEW YORK (GenomeWeb) – Biocartis said today that it is collaborating with medical research charity MRC Technology to develop molecular diagnostic tests for use on the Biocartis fully automated Idylla platform.

Under the terms of the agreement, MRCT will act as a development contractor and Biocartis will be responsible for the commercialization of the tests under its own label. Financial details of the partnership were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.